Home > Dermatology > PFGC 2021 > Letter from the Editor

Letter from the Editor

Prof. Peter C.M. van de Kerkhof, Radboud University Medical Center, the Netherlands
PFGC 2021
Dear Colleague,

Psoriasis from Gene to Clinic is a congress for Dermatologists with a special interest in psoriasis, which is organised once every 3 years. For the meeting in December 2021, the expectation was an in-person congress. For dermatologists from outside the UK, travelling to London was a challenge, which resulted in a hybrid congress with life communications in the UK and virtual presentations and audience in the rest of the world.

Also, this congress of psoriasis from gene to clinic brought innovations in discussion. Psoriasis is a showcase of translational medicine with pathogenesis-based treatments and biomarkers in development.

New information was reported on genetic markers and their relevance to the treatment of psoriasis. The information on comorbidities was not only limited to psoriatic arthritis and metabolic syndrome and cardiovascular. New information on the association between psoriasis and cancers was reported.

IL-36 signalling and IL-36 inhibition as a therapeutic principle is an innovation in the treatment of generalised pustular psoriasis.

The long-term management of psoriasis with biologics is enriched by real practice studies. In particular, early active intervention and dosage reduction in patients on maintenance treatment are areas of interest.

Last but not least, new information was communicated on COVID-19 and psoriasis, in particular related to the treatment of psoriasis.


Best Regards,


Peter CM van de Kerkhof


Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was a board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.

Conflict of Interest Statement:Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma,Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant.Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.


Posted on